Physician profile
Shepard A Adler
NPI 1366403974
$1,954.79
in general payments reported to CMS, 2019-2025
10 companies · $913 in 2025
The $913 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $62.24 · 2021: $260 · 2024: $541 · 2025: $913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,454.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $690.32 | 2021-2025 | Tryptyr, Rhopressa, Rocklatan |
| Bausch & Lomb Americas INC. | $371.11 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Amgen INC. | $187.34 | 2024 | Tepezza |
| Ocular Therapeutix, INC. | $127.40 | 2024 | Dextenza |
| Sun Pharmaceutical Industries INC. | $125.95 | 2020-2021 | |
| Kala Pharmaceuticals, INC. | $121.95 | 2021 | |
| Aerie Pharmaceuticals, INC. | $112.07 | 2019 | |
| Dompe US, INC. | $101.36 | 2024 | Oxervate |
| Coopervision INC. | $66.00 | 2019 | |
| Glaukos Corporation | $51.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shepard Adler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.